Scroll for more
news Sep 2, 2016

Opening Up Drug Discovery

image goes here

Extract from 'Laboratory News. September 2016' by Professor Jackie Hunter, CEO BenevolentBio

It is my natural tendency to believe that trans­parency in general is a good thing so long as it  doesn't hinder competitiveness or expose people to risk of harm. When I joined the pharmaceutical industry in the 1980s, there was a real sensitivity in sharing any information since the competition between companies was fierce and information was seen as a competitive commodity. Publications were not encouraged and data around pipelines and portfolios a closely guarded secret. 'Nega­tive' clinical data was not shared either and this secrecy contributed to the negative view of the pharmaceutical industry that still pervades today.

This is unfortunate because one of the reasons I joined the industry was because I thought discovering and developing new medicines was a laudable and worth­while endeavour, especially as I myself used medicines for my asthma on a daily basis. So where has the situa­tion improved across the R&D process in the past two decades and where are improvements still necessary?

There have been a number of pressures on the indus­try aside from lack of trust. First the escalating costs of developing new medicines - today it is estimated that this is in the order of $1-$1.SB per drug. This incorporates the cost of failure and ultimately the cost of failure has risen so greatly that it is no longer sustain­able. In addition, there have been increasing regulatory demands and uncertainties around reimbursement and pricing. These pressures have led to the adoption of a more open innovation mind set within the industry that has seen much more pre-competitive collaboration and data sharing especially in the early stages of drug discovery and development. 

 

Read the full article here